| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| METHYLDOPA (is an active metabolite)
| METHYLDOPA |
CARDIOVASCULAR | ORAL | VD 44.8 LITER (65 KILOGRAM) PPB 15 PERCENT Cl 13.6 LITER / HOUR (65 KILOGRAM) HT 1.8 HOUR SOLUBILITY SOLUBLE IN WATER | DOPA DECARBOXYLASE | ADRENERGIC RECEPTOR ALPHA-2 AGONIST CHEMBL2095158 ADRENERGIC RECEPTOR ALPHA-2 P08913 ALPHA-2A ADRENERGIC RECEPTOR HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL MONOAMINE RECEPTOR ADRENERGIC RECEPTOR | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| METHYLDOPATE DISCONTINUED (has an active metabolite)
| METHYLDOPATE |
CARDIOVASCULAR | INJECTION | DOPA DECARBOXYLASE | ADRENERGIC RECEPTOR ALPHA-2 AGONIST CHEMBL2095158 ADRENERGIC RECEPTOR ALPHA-2 P08913 ALPHA-2A ADRENERGIC RECEPTOR HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL MONOAMINE RECEPTOR ADRENERGIC RECEPTOR | EMA | ||||
